Chronic Pain – Current Treatment – Detailed, Expanded Analysis (US)
The treatment of chronic pain continues to provide unique challenges to physicians owing to the heterogeneity of pain pathophysiology within and across different chronic pain subtypes and the absence of targeted mechanism-based therapies. As a result, it is difficult to achieve adequate analgesia in all patients despite the extensive armamentarium of chronic pain therapies, including the increasing availability of cost-effective generic treatments. The high cost of chronic pain management stemming from a long duration of treatment and the many lines of therapy often required to maintain analgesic effects are exacerbated by the growth of the market due in part to the increasing prevalence of key population segments, including osteoarthritis pain and chronic back pain. Unfortunately, no truly novel analgesic solutions for chronic pain have launched in recent years. Fixed-dose combinations of nonsteroidal anti-inflammatory drugs and abuse-deterrent formulations of opioid analgesics offer incremental advantages in safety and tolerability but struggle to compete against long-generic and firmly entrenched standards of care.
How is chronic pain being treated in the United States today, and what are the drivers and constraints influencing physicians’ treatment decisions?
What factors drive switching between or discontinuation of select analgesics?
What impact has the COVID-19 pandemic had on the prescribing of analgesics for chronic pain?
What impact has the more-recent launch of Burke’s Consensi (branded celecoxib / amlodipine) had on physician prescribing behavior for chronic pain?
Geography: United States
Primary research: Survey of 51 U.S. primary care physicians and 51 U.S. pain specialists
Key drugs covered: Hysingla ER, OxyContin, Nucynta ER, Belbuca, Xtampza ER, Consensi, pregabalin, celecoxib, diclofenac topical gel
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Chronic Pain - Current Treatment - Detailed, Expanded Analysis (US)
Current Treatment Chronic Pain US July 2021
Arava Suresh, M.Pharm.
Suresh Arava, M.Pharm., is a research associate on the CNS/Ophthalmology Disorders team at Clarivate. He earned a master’s degree in pharmaceutical administration and management from Manipal University in India.